Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Clinical Effects of Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders). Pilot Study

NCT05137938 is registered in ClinicalTrials.gov with Centre for Addiction and Mental Health as lead sponsor.

NCT NCT05137938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05137938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Clinical Effects of Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders). Pilot Study
Lead sponsor
Centre for Addiction and Mental Health
Phase
Not applicable
Overall status
Completed
Start date
October 25, 2021
Completion date
July 24, 2023
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression